GAIA BioMedicine Initiates Development of Proprietary Cell Processing Center (CPC) at “f-labs Kyushu University Hospital” – Paving the Way for Commercial Production of Innovative Cancer Therapies –

GAIA BioMedicine Inc. (Headquarters: Fukuoka City, Fukuoka; President and CEO: Kazuyuki Kuramori; hereinafter “GAIA”) announced today that it has begun the development of its proprietary Cell Processing Center (CPC) within ” f-labs Kyushu University Hospital ” (hereinafter “f-labs”). f-labs is a rental wet lab and startup support facility for life science companies produced by Fukuoka Jisho Co., Ltd. (Headquarters: Fukuoka City, Fukuoka; President and Representative Director: Ichiro Enomoto; hereinafter “Fukuoka Jisho”) on the Kyushu University Hospital campus. This project is being undertaken in close collaboration with Fukuoka Jisho.

Background and Objectives:
GAIA received investment from Fukuoka Jisho in 2023, and the construction of this CPC marks the first concrete collaborative project between the two companies. With the establishment of this CPC, GAIA aims to solidify a robust supply system that extends beyond the manufacturing of investigational drugs to include future commercial production. Through this strong partnership, the companies are committed to accelerating the realization and widespread adoption of innovative cancer treatments.

About the Opening Ceremony:
The opening ceremony for f-labs was held on January 26, 2026. Yoshikazu Yonemitsu, M.D., Ph.D. (CSO/CMO; Professor, Graduate School of Pharmaceutical Sciences, Kyushu University), took the stage at the event. In his address, Prof. Yonemitsu discussed the prospects for future business expansion utilizing the new CPC and expressed his high expectations for the role of f-labs as a key hub for life sciences.

https://prtimes.jp/main/html/rd/p/000000014.000022997.html

<f-labs Official HP>
https://fj-lifescience.jp/

Share on